Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Noom and Mochi represent two distinct approaches to weight management gaining traction in clinical practice. Noom operates as a behavioral health app with psychological coaching; Mochi functions as a telehealth platform dispensing GLP-1 medications like semaglutide. Each model reports engagement metrics, but they address fundamentally different intervention points in weight regulation.
Patients exploring these platforms often wonder whether behavioral support alone or medication-assisted care better fits their goals and genetics. This comparison matters because treatment response varies significantly based on individual metabolic factors, lifestyle constraints, and underlying physiological predispositions. PlexusDx supports this personalization through precision genetic testing alongside compounded medication options.
Noom: Behavioral Psychology and Habit Tracking Framework
Noom uses cognitive behavioral therapy (CBT) principles delivered through a mobile app, pairing food logging with daily lessons on psychology, nutrition, and behavior change. Users receive real-time feedback from coaches and engage with peer communities. Noom does not prescribe medications; instead, it focuses on retraining eating patterns and building sustainable habits.
Clinical studies on behavioral interventions show modest weight loss of 5–10% for engaged users over six months. Noom's model assumes that psychological awareness and habit modification can reduce caloric intake without pharmaceutical support. This approach appeals to patients seeking non-medication options or those with contraindications to GLP-1 therapy.
Mochi: Telehealth GLP-1 Medication Dispensing
Mochi is a telehealth platform that connects patients to licensed providers for GLP-1 prescription and ongoing management. Patients complete a medical intake, speak with a clinician, and receive medications like semaglutide injections or tablets delivered directly. Mochi emphasizes convenience and accessibility to pharmacological intervention without traditional office visits.
GLP-1 medications work by enhancing satiety signaling and slowing gastric emptying, resulting in greater weight loss—typically 10–22% depending on medication, dose, and adherence—compared to behavioral-only interventions. Mochi positions itself as a faster, more direct path to pharmaceutical support for eligible candidates.
Clinical Comparison Framework
Direct comparison of Noom and Mochi reveals trade-offs in mechanism, evidence strength, cost, and patient selection. Neither is universally superior; clinical outcomes depend on individual readiness, metabolic factors, contraindications, and adherence. The table below summarizes key distinctions to guide informed decision-making.
| Dimension |
Noom |
Mochi |
Consideration |
| Primary Mechanism |
Behavioral coaching + habit change |
GLP-1 medication + virtual care |
Behavioral alone vs. pharmacological intervention |
| Typical Weight Loss Range |
5–10% over 6 months (engaged users) |
10–22% depending on medication and adherence |
GLP-1 shows stronger early response; behavior change sustains long-term |
| Medication Required |
No |
Yes (semaglutide, tirzepatide, or similar) |
Eligibility depends on BMI, comorbidities, contraindications |
| Time to Provider Consultation |
Coach interaction within app, no physician visit |
Virtual appointment before prescription |
Mochi faster to medication; Noom requires app enrollment |
| Cost Range |
$40–$200 per month subscription |
$150–$400+ per month for medications and consultations |
Noom less expensive upfront; Mochi higher but includes medication |
| Contraindications/Exclusions |
Minimal medical screening |
Medullary thyroid cancer history, GLP-1 allergy, pancreatitis risk |
Mochi requires medical clearance; Noom more universally accessible |
Metabolic and Genetic Factors Influencing Treatment Selection
Response to both behavioral and pharmacological interventions varies based on genetic predispositions in appetite regulation and energy metabolism. Variants in genes like GLP1R (GLP-1 receptor), GIPR (glucose-dependent insulinotropic peptide receptor), FTO, and MC4R influence how well individuals respond to GLP-1 medications or derive benefit from behavioral coaching.
A patient with genetic predispositions favoring strong GLP-1 signaling may see superior outcomes with Mochi's pharmaceutical approach, while someone with genetic resilience to behavioral changes might benefit from Noom's intensive coaching. Precision genetic testing can help contextualize these pathways and inform more individualized care conversations between patient and provider.
Noom vs. Mochi: Adherence and Long-Term Sustainability
Noom's success depends on consistent app engagement and intrinsic motivation to change eating behaviors. Long-term adherence requires sustained habit formation; many users experience weight regain if coaching ends and new behaviors are not consolidated. Behavioral interventions work best in patients with high health literacy and willingness to invest daily effort.
Mochi's medication-based model requires ongoing supply and clinical monitoring, but adherence is often simpler once started—patients need consistent refills rather than daily behavioral effort. However, GLP-1 discontinuation typically leads to weight regain within months, meaning long-term commitment and cost are necessary. Combination approaches (behavioral support plus medication) may improve outcomes compared to either alone.
Safety Considerations and Medical Eligibility
Noom carries minimal medical risk because it involves no medications; however, psychological coaching may be ineffective or even harmful if underlying eating disorders, severe mental health conditions, or undiagnosed metabolic disease are present. Medical clearance is still prudent before starting any intensive behavioral program.
Mochi requires standard telehealth screening for GLP-1 eligibility: no personal or family history of medullary thyroid carcinoma, no severe pancreatitis, stable kidney and liver function, and appropriate BMI. GLP-1 medications carry nausea, vomiting, constipation, and rare but serious risks like thyroid tumors in animal models and diabetic retinopathy complications. Mochi clinicians should verify these contraindications; patients must report all medications and conditions.
How PlexusDx Supports a More Personalized Approach
PlexusDx recognizes that neither Noom's behavioral framework nor Mochi's off-the-shelf GLP-1 approach accounts for individual genetic predispositions in peptide hormone pathways. Variants in GLP1R, GIPR, FTO, and MC4R genes may predict which patients benefit most from GLP-1 activation versus behavioral intervention, or whether a combined strategy is optimal.
The PlexusDx Precision Peptide Genetic Test ($99 add-on or $298 standalone) analyzes key variants in these pathways to provide context for treatment selection conversations. The test does not guarantee medication response or predict exact outcomes; rather, it may help patients and providers explore which approach—behavioral, pharmacological, or combined—aligns with their genetic landscape and clinical goals.
If a patient decides that compounded GLP-1 therapy fits their situation, PlexusDx offers semaglutide ($149/mo) and tirzepatide ($249/mo) from licensed 503A compounding pharmacies, alongside lower-dose options like the Microdose GLP-1 Protocol ($129/month). These compounded formulations provide an alternative to branded or telehealth-dispensed medications, supported by provider oversight and precision genetic insight.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the key difference between Noom and Mochi?
Noom is a behavioral health app using psychology and habit coaching without medications; Mochi is a telehealth platform that prescribes and manages GLP-1 medications. Noom suits patients preferring non-pharmaceutical approaches; Mochi suits those eligible for and seeking medication-assisted weight management.
Which shows better clinical weight loss results, Noom or Mochi?
Mochi's GLP-1 medications typically produce 10–22% weight loss, while Noom's behavioral intervention averages 5–10%. GLP-1 offers faster, larger initial loss; behavioral change may sustain results better long-term if habits truly change.
Can I use Noom and Mochi together?
Possibly, though neither platform explicitly markets dual use. A patient on Mochi's GLP-1 could theoretically benefit from Noom's behavioral coaching to reinforce habits. Discuss combined approaches with your provider to ensure they don't conflict or create redundancy.
How much does Noom or Mochi cost?
Noom ranges $40–$200/month depending on subscription tier. Mochi typically costs $150–$400+/month for medications and virtual consultations. Costs vary by location, medication choice, and insurance coverage.
How does genetic testing help choose between Noom and Mochi?
PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP1R, GIPR, FTO, and MC4R pathways. This context may help clarify whether you're a stronger responder to GLP-1 therapy or behavioral intervention, supporting a personalized decision with your provider.
What if I'm not eligible for Mochi's GLP-1 medications?
Contraindications include medullary thyroid cancer history, severe pancreatitis, or certain kidney/liver conditions. If ineligible for GLP-1, Noom's behavioral model or other non-pharmacological approaches may be safer. Consult your doctor for alternatives.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Orderly Meds vs Henry Meds: Clinical Provider Models for GLP-1 Therapy
Remedy Meds Mounjaro: Tirzepatide Access and Clinical Considerations